Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Jul. 01, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 29,389	$ 30,186
Accounts receivable, net	119,636	136,295
Inventory	96,276	84,766
Prepaid and other current assets	15,337	18,551
Current assets attributable to discontinued operations	0	2,777
Total current assets	260,638	272,575
Property and equipment, net	41,862	27,456
Goodwill	7,462	7,462
Intangible assets, net	505,223	639,851
Operating lease assets	15,238	16,690
Investment and other assets	6,539	2,621
Long-term assets attributable to discontinued operations	0	405,994
Total assets	836,962	1,372,649
Current liabilities:
Accounts payable	41,364	36,697
Accrued liabilities	121,748	111,570
Current portion of long-term debt	11,320	33,056
Other current liabilities	4,672	3,607
Current liabilities attributable to discontinued operations	0	119,087
Total current liabilities	179,104	304,017
Long-term debt, less current portion	374,568	385,010
Deferred income taxes	0	2,248
Contingent consideration	17,958	17,431
Other long-term liabilities	31,991	22,810
Long-term liabilities attributable to discontinued operations	0	228,911
Total liabilities	603,621	960,427
Commitments and contingencies (Note 11)
Stockholders’ Equity
Additional paid-in capital	490,598	490,576
Accumulated deficit	(308,137)	(165,306)
Accumulated other comprehensive income (loss)	655	(110)
Total stockholders’ equity attributable to Bioventus Inc.	183,195	325,238
Noncontrolling interest	50,146	86,984
Total stockholders’ equity	233,341	412,222
Total liabilities and stockholders’ equity	836,962	1,372,649
Common Class A
Stockholders’ Equity
Common stock, value	63	62
Common Class B
Stockholders’ Equity
Common stock, value	$ 16	$ 16